IceCure Medical

What IceCure Medical does

IceCure Medical Ltd. is an Israeli medical device company founded in 2006 that develops and markets the ProSense Cryoablation System, a liquid nitrogen-based platform that destroys tumors by generating ultra-cold temperatures below -170°C. The system uses a single cryoprobe design that can be relocated up to three times per patient during a procedure, creating large lethal ice balls under imaging guidance. ProSense received FDA De Novo marketing authorization in October 2025 as the first and only device cleared for the local treatment of early-stage low-risk breast cancer in women aged 70 and above. Additional clinical applications include kidney cancer, lung cancer, liver tumors, musculoskeletal tumors, palliative care, and benign breast fibroadenomas. The company is publicly traded on Nasdaq (ICCM) and the Tel Aviv Stock Exchange, headquartered in Caesarea, Israel, with 51–100 employees.

The company operates a capital equipment plus disposable consumables business model, generating revenue from sales of the ProSense console and recurring single-use cryoprobes. FY2025 revenue was $3.4 million, up 3% from $3.3 million in 2024, with gross margin declining to 36% from 44% due to increased raw material and subcontractor costs. Net loss for 2025 was approximately $15.1 million. The company uses direct sales in the United States targeting hospitals, cancer centers, breast surgeons, and interventional radiologists, and exclusive distribution partners internationally including KTR Medical in Brazil and Terumo Corporation in Japan. Breast cancer cryoablation procedures are reportable under CPT code 0581T with approximately $4,000 facility fee reimbursement.

The company's clinical evidence base includes the ICE3 trial (206 patients across 19 U.S. sites showing 3.1% local recurrence rate at 5 years), the ICESECRET kidney cancer trial (114 patients showing 89.4% recurrence-free rate at 5 years for tumors ≤3 cm), and the FDA-approved ChoICE post-marketing study (planned 400 patients across 30 U.S. sites). Key commercial and clinical sites include Cleveland Clinic, University of Michigan, Massachusetts General Hospital, West Cancer Center, Adventist Health Glendale, and Thomas Hospital. The company holds patents on next-generation XSense cryogenic connector and cryogenic pump technology in the U.S., Europe, and Japan through 2041, and has raised approximately $25 million across multiple financing rounds in 2025–2026 to support commercial expansion.

Name

IceCure Medical

Legal name

IceCure Medical Ltd.

Website

https://icecure-medical.com

Company type

Public

Founded year

2006

Operating status

Operating

Headcount range

51–100 employees

Short description

IceCure Medical develops and markets the ProSense Cryoablation System, a liquid nitrogen-based medical device for minimally invasive tumor destruction in breast cancer, kidney cancer, lung cancer, and fibroadenomas, serving hospitals, cancer centers, breast surgeons, and interventional radiologists globally.

Ownership category

akta.pro rank

Product category

Cryoablation Medical Devices

NAICS

Medical Equipment and Supplies Manufacturing (3391), Surgical Appliance and Supplies Manufacturing (339113)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Sample Preparation, Storage & Cryogenics (Freezers, Cryovials, Cryostats) (HLAGAIAJ)

Keywords

• Cryoablation systems
• Medical device manufacturing
• Minimally invasive oncology
• Breast cancer treatment
• Interventional radiology devices

Headquarters

HQ city

Caesarea

HQ country

Israel

HQ region

Middle East

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

1. ProSense System and Cryoprobe Sales: IceCure generates revenue through the sale of ProSense cryoablation systems (capital equipment) and disposable cryoprobes. 2025 full-year revenue was $3.4 million, up 3% from $3.3 million in 2024. North America sales grew 42% in 2024.
2. System Sales and Probe Revenue: The company expects U.S. revenue from ProSense systems and cryoprobes to increase more than 30% in Q1 2026 compared to Q1 2025. The company projects continued commercial momentum in 2026 with additional reimbursement coverage expected.

Pricing tiers

Go-to-market motion2 records

Distribution channels4 records

Marketing channels6 records

Core offering

IceCure Medical develops, manufactures, and commercializes the ProSense Cryoablation System, a liquid nitrogen-based medical device platform that uses ultra-cold temperatures (below -170°C) to minimally invasively destroy tumors via a single cryoprobe. The system is sold as capital equipment with disposable cryoprobes to hospitals, cancer centers, and clinics, with FDA clearance for low-risk breast cancer and additional regulatory approvals for kidney, lung, liver, and musculoskeletal tumors globally.

Product overview

IceCure Medical offers the ProSense Cryoablation System as its flagship product, a liquid nitrogen-based medical device platform that provides minimally invasive tumor destruction through freezing technology. The system includes the main console unit, single cryoprobes, and is supported by next-generation XSense cryogenic connector technology. ProSense is FDA-cleared for breast cancer treatment and has regulatory approvals for kidney, lung, liver, and other tumor applications across global markets.

Differentiator

Problem solved

Functional benefit

Brands

• ProSense: Liquid nitrogen-based cryoablation system for tumor destruction, FDA-cleared for low-risk breast cancer treatment
• XSense

Products and services

• ProSense Cryoablation System A liquid nitrogen-based cryoablation system that destroys tumors by freezing them using ultra-cold temperatures lower than -170°C, creating large lethal ice balls for tumor destruction in benign and cancerous lesions including breast, kidney, lung, and liver tumors. Sold to hospitals, cancer centers, and clinics for outpatient cryoablation procedures.
• ProSense Cryoprobes Single cryoprobe system available in various sizes that can be relocated up to three times per patient during a single procedure to treat larger tumors or multiple lesions. Sold as disposable consumables to accompany the ProSense capital equipment.
• XSense Cryogenic Connector Technology Next-generation cryoablation technology featuring improved cryogenic pump technology and cryogenic system connector designed to enhance safety and cooling rates in cryoablation procedures. Designed to integrate with the ProSense cryoablation platform.

Quantifiable outcome

• 3.1% local recurrence rate within 5 years for breast cancer patients treated with cryoablation and endocrine therapy (ICE3 trial)
• +7 more outcomes

Named customers7 records

Segments4 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Two partnerships are on record, tiered core.

• KTR MedicalcoreChannel Partner/ Reseller/ DistributorKTR Medical serves as the exclusive importer and distributor of IceCure's ProSense cryoablation system in Brazil. The partnership has enabled commercial procedures for breast, lung, kidney cancer, and musculoskeletal tumors at key Brazilian medical centers following FDA authorization. An independent 750-patient study (SIX trial) led by Dr. Vanessa Sanvido is underway in Brazil.
• Terumo CorporationcoreChannel Partner/ Reseller/ DistributorTerumo Corporation is IceCure's exclusive distributor in Japan. The company participated in the Japanese Breast Cancer Society Conference presenting clinical data. Terumo is expected to submit ProSense for regulatory approval to Japan's PMDA in H2 2026 for breast cancer indication.

Scale indicators14 records

Recent moves8 records

Expansion highlights8 records

Direct peers

• HealthTronics: HealthTronics provides cryoablation services and equipment for urology and oncology, including prostate and kidney tumor treatments. As a service-and-device operator in the same cryoablation category, it overlaps with ProSense's interventional radiology use cases.
• AngioDynamics: AngioDynamics manufactures cryoablation systems (Cryo-Hit, Endocare product lines) used for prostate, kidney, and other tumor ablation. It is a direct competitor to IceCure's ProSense in the cryoablation device market, with established US sales coverage in interventional oncology.
• Boston Scientific (Galil Medical): Boston Scientific acquired Galil Medical, a pioneer in argon-based cryoablation technology for kidney, prostate, and other tumors. As the largest incumbent in percutaneous cryoablation, it competes directly with ProSense in interventional radiology suites globally.

Broad incumbents

• Varian Medical Systems (Siemens Healthineers): Varian is a leading radiation oncology and interventional oncology platform serving hospitals treating breast, lung, and other solid tumors. As an established incumbent in the broader oncology treatment device market, it competes indirectly with ProSense for capital budgets and physician mindshare.
• Medtronic: Medtronic operates a large interventional oncology and minimally invasive therapies franchise including ablation technologies. It is a broad incumbent that competes with ProSense across multiple tumor types via its established global sales infrastructure and hospital relationships.
• Hologic: Hologic is a major women's health company with breast biopsy, diagnostics, and breast surgery products. It serves the same breast surgeon customer base as IceCure and is a broad incumbent in the breast cancer workflow where ProSense cryoablation competes as a treatment alternative.

Emerging players

• EDAP TMS: EDAP TMS markets HIFU (high-intensity focused ultrasound) ablation devices, primarily for prostate cancer and other urological conditions. It is an emerging player in non-surgical tumor ablation, sharing IceCure's strategy of displacing surgery with minimally invasive ablative therapy.
• Sensus Healthcare: Sensus Healthcare markets superficial radiation therapy (SRT) systems used for non-melanoma skin cancer and is exploring breast cancer indications. It is an emerging player pursuing minimally invasive office-based alternatives for cancer treatment, with overlapping physician adoption dynamics.
• Merit Medical Systems: Merit Medical manufactures interventional radiology and oncology devices, including ablation and embolization products. It overlaps with ProSense in serving interventional radiologists who perform percutaneous tumor ablations across kidney, lung, and other solid tumors.

Others

• Integra LifeSciences: Integra LifeSciences produces a broad portfolio of surgical, neurosurgical, and regenerative tissue products. It is an adjacent medical device manufacturer serving surgical oncology and interventional specialists, but does not directly compete in cryoablation.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

• Xx.com/IceCureMedical
• YouTubeyoutube.com/channel/UClq8QWZZDfNYwfKl6GSXRmw
• Facebookfacebook.com/IceCureMedical
• LinkedInlinkedin.com/company/461122
• Instagraminstagram.com/icecure_medical/?hl=en
• TikToktiktok.com/@icecure_medical

Compliance7 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds10 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about IceCure Medical